Literature DB >> 14521803

Consolidation/maintenance chemotherapy for ovarian cancer.

Maurie Markman1.   

Abstract

A recently reported randomized trial has demonstrated that administration of single-agent paclitaxel to women with advanced ovarian cancer who attain a clinically defined complete response to platinum/paclitaxel-based chemotherapy can substantially improve progression-free survival. Whether this strategy will improve overall survival in this clinical setting remains uncertain.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14521803     DOI： 10.1007/s11912-003-0005-y

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  23 in total

1.  The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: "maintenance" therapy reconsidered.

Authors:  D M Gershenson; M F Mitchell; N Atkinson; E G Silva; J J Kavanagh; M Morris; T W Burke; D Warner; J T Wharton
Journal:  Gynecol Oncol       Date:  1992-10       Impact factor: 5.482

2.  1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings.

Authors:  B Fisher; P Carbone; S G Economou; R Frelick; A Glass; H Lerner; C Redmond; M Zelen; P Band; D L Katrych; N Wolmark; E R Fisher
Journal:  N Engl J Med       Date:  1975-01-16       Impact factor: 91.245

3.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

Authors:  M J Piccart; K Bertelsen; K James; J Cassidy; C Mangioni; E Simonsen; G Stuart; S Kaye; I Vergote; R Blom; R Grimshaw; R J Atkinson; K D Swenerton; C Trope; M Nardi; J Kaern; S Tumolo; P Timmers; J A Roy; F Lhoas; B Lindvall; M Bacon; A Birt; J E Andersen; B Zee; J Paul; B Baron; S Pecorelli
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

4.  Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.

Authors:  T B Hakes; E Chalas; W J Hoskins; W B Jones; M Markman; S C Rubin; D Chapman; L Almadrones; J L Lewis
Journal:  Gynecol Oncol       Date:  1992-06       Impact factor: 5.482

5.  A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).

Authors:  K Bertelsen; A Jakobsen; J Strøyer; K Nielsen; E Sandberg; J E Andersen; S Ahrons; M Nyland; P Hjortkjaer Pedersen; G Larsen
Journal:  Gynecol Oncol       Date:  1993-04       Impact factor: 5.482

6.  European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

Authors:  E A Eisenhauer; W W ten Bokkel Huinink; K D Swenerton; L Gianni; J Myles; M E van der Burg; I Kerr; J B Vermorken; K Buser; N Colombo
Journal:  J Clin Oncol       Date:  1994-12       Impact factor: 44.544

7.  A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma.

Authors:  G A Omura; C P Morrow; J A Blessing; A Miller; H J Buchsbaum; H D Homesley; L Leone
Journal:  Cancer       Date:  1983-03-01       Impact factor: 6.860

Review 8.  Paclitaxel (taxol)

Authors:  E K Rowinsky; R C Donehower
Journal:  N Engl J Med       Date:  1995-04-13       Impact factor: 91.245

9.  Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

Authors:  E L Trimble; J D Adams; D Vena; M J Hawkins; M A Friedman; J S Fisherman; M C Christian; R Canetta; N Onetto; R Hayn
Journal:  J Clin Oncol       Date:  1993-12       Impact factor: 44.544

10.  Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.

Authors:  M K Tuxen; G Sölétormos; P Dombernowsky
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640
View more
  1 in total

1.  Are three additional cycles of chemotherapy useful in patients with advanced-stage epithelial ovarian cancer after a complete response to six cycles of intravenous adjuvant paclitaxel and carboplatin?

Authors:  Hee Seung Kim; Noh-Hyun Park; Hyun Hoon Chung; Jae Weon Kim; Yong-Sang Song; Soon-Beom Kang
Journal:  Jpn J Clin Oncol       Date:  2008-05-27       Impact factor: 3.019
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.